Anlon Healthcare IPO will open on August 26, 2025, and close on August 29, 2025. It is a Book Build Issue through which the company aims to raise approximately ₹121.03 crores via a fresh issue of shares, each having a face value of ₹10. The IPO price band has been fixed at ₹86 to ₹91 per share. The quota distribution is 10% for retail investors, 75% for QIBs, and 15% for HNIs. The shares of Anlon Healthcare are scheduled to be listed on BSE and NSE on September 3, 2025, with the allotment date set for September 1, 2025.

In terms of financial performance, the company reported revenue of ₹66.69 crores in 2024 compared to ₹113.12 crores in 2023. Its profit rose to ₹9.66 crores in 2024 from ₹5.82 crores in 2023. Based on these financials, the IPO is considered suitable for long-term investment.

About Anlon Healthcare IPO

Anlon Healthcare Limited, founded in 2013, is one of the growing chemical manufacturing companies engaged in the manufacturing of 2 things: 1. high purity advanced pharmaceutical intermediates used as raw materials for making active pharmaceutical ingredients (APIs). 2. APIs are used in medicines like tablets, capsules, ointments, syrups, as well as in nutraceuticals, personal care, and animal health products. Its portfolio consists of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), nutraceutical APIs, and ingredients for personal care and veterinary use.

Moreover, among a few other companies, Anlon Healthcare is an Indian maker of loxoprofen sodium dihydrate, which is an API widely useful to treat severe pain like arthritis, back pain, frozen shoulder, tooth pain, or post-surgery recovery. The company had 105 employees (excluding trainees) and 8 contract workers as of January 31, 2025. As of the date of filing DRHP, the company has 65 commercial products, 28 at the pilot stage, and 49 in laboratory testing.